	US 12,122,844 B2
	Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
Ronald G. Crystal, New York, NY (US); Stephen M. Kaminsky, Bronx, NY (US); Martin J. Hicks, New York, NY (US); and Viviane Tabar, New York, NY (US)
Assigned to Cornell University, Ithaca, NY (US); and Memorial Sloan-Kettering Cancer Center, New York, NY (US)
Filed by Cornell University, Ithaca, NY (US); and Memorial Sloan-Kettering Cancer Center, New York, NY (US)
Filed on Jul. 13, 2020, as Appl. No. 16/927,675.
Application 16/927,675 is a continuation of application No. 14/426,347, previously published as PCT/US2013/059674, filed on Sep. 13, 2013.
Claims priority of provisional application 61/700,599, filed on Sep. 13, 2012.
Prior Publication US 2021/0171656 A1, Jun. 10, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01); C07K 16/22 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/3053 (2013.01) [A61K 48/005 (2013.01); C07K 16/22 (2013.01); C07K 16/24 (2013.01); C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); A61K 48/00 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C12N 2750/14141 (2013.01); C12N 2799/025 (2013.01)]

14 Claims

1. A method of inhibiting glioblastoma, a glioma or a glial tumor in a human, comprising: intracranially or intracisternally administering to the human, during or after resection of the glioblastoma, glioma or glial tumor, a composition comprising an effective amount of a recombinant adeno-associated virus (rAAV) comprising:

i) an expression vector encoding an antibody directed against vascular endothelial growth factor (VEGF), wherein the antibody comprises SEQ ID NO:4 and SEQ ID NO:5; or ii) an expression vector encoding an antibody directed against epidermal growth factor receptor (EGFR), wherein the antibody comprises SEQ ID NO:8 and SEQ ID NO:9, wherein the rAAV comprises an AAVrh10 capsid.